Result of AGM and AGM Statement

Mediwatch plc

("Mediwatch" or "the Company" or "the Group")

22 April 2013

Result of AGM and AGM Statement

At 11a.m. today, Omer Karim, Chairman of Mediwatch delivered the following statement at the Company's annual general meeting:

"It should be no surprise that 2012 was a challenging year. Whilst in the long term, demographically, urology is a sector with increasing needs, in the short term health budgets around the world continue to be under pressure in these straightened times. Mediwatch has worked hard to maintain profitability by cost cutting expenses and re-engineering products.

After a long development period, Mediwatch is proud to announce that it has started selling PSAwatch, a quantitative point-of-care test for PSA using whole blood. PSAwatch is steadily increasing its share of the almost 50 million PSA tests that are performed annually worldwide.

Mediwatch's vision for the future is to develop affordable equipment for the treatment of conditions in its targeted clinical areas. 2013 will be a year filled with new product launches. The first of these a new urodynamic range of Clinic and Encompass, the new Nano, a new procedure couch and the tablet Portaflow were well received at European Association of Urologists meeting in Milan in March. There is more to come later in the year.

I am also pleased to report that the Group is currently trading in line with management's budgets and, whilst our markets around the world remain fragile, we expect to meet market expectations for the year."

All resolutions proposed at the annual general meeting were duly passed save for resolution 7 (resolution 7 related to disapplication of pre-emption rights).

Enquiries:

Mediwatch plc

+44 (0)1788 547 888

Dr Philip Stimpson, Chief Executive Officer

Mark Hughes, Chief Financial Officer

SP Angel Corporate Finance LLP

Nomad and broker

+44 (0)20 3463 2260